Drug Trial Radar · NCT05646706
A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)
Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,407
Actual
Start
Jan 4, 2023
Primary completion
Oct 30, 2024
Study completion Nov 26, 2024
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Dec 12, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the "dummy" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. In the first part of the study, participants will get one injection once a week until they reach the planned dose. The second part of the study, which might last a couple of months, is a transition period, where participant will get three injections, taken right after each other, once a week. The duration of the study intervention (trial product and lifestyle intervention) will be 72 weeks followed by a 9-week follow-up period without study interventions.
Conditions
- Obesity
Interventions
SemaglutideDrug
Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
SemaglutideDrug
Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
PlaceboDrug
Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Semaglutide 7.2 mg Versus Placebo: Relative Change in Body WeightTime frame: Baseline (week 0), End of treatment (week 72)
- Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)Time frame: At week 72
Locations
107 sites in 12 countries. Site status is shown where the registry gives one.
Univ of Alabama Birmingham
Birmingham, Alabama
Chambliss Clinical Trials, LLC
Montgomery, Alabama
Healthscan Clinical Trials,LLC.
Montgomery, Alabama
Diablo Clinical Research, Inc.
Walnut Creek, California
Jacksonville Ctr For Clin Res
Jacksonville, Florida
Florida Inst For Clin Res LLC
Orlando, Florida
Florida Institute For Clinical Research LLC
Orlando, Florida
East West Med Res Inst
Honolulu, Hawaii
Midwest Inst For Clin Res
Indianapolis, Indiana
AMC Community Endocrinology
Albany, New York
University of North Carolina
Chapel Hill, North Carolina
PharmQuest Life Sciences LLC
Greensboro, North Carolina
Medical University Of South Carolina
Charleston, South Carolina
Amarillo Med Spec LLP
Amarillo, Texas
Elligo Clin Res Centre
Austin, Texas
Velocity Clin Res, Dallas
Dallas, Texas
UT Southwestern Medical Center-CRU
Dallas, Texas
DCOL Ctr for Clin Res
Longview, Texas
Sugar Lakes Family Practice PA
Sugar Land, Texas
National Clin Res Inc.
Richmond, Virginia
Selma Medical Associates
Winchester, Virginia
Medical centre Zdrave 1 OOD
Kozloduy, Bulgaria
Medical center Hippocrates Lukovit EOOD
Lukovit, Bulgaria
IPMC - Dr. Elizabeta Dimitrova
Petrich, Bulgaria
Medical center Smolyan clinical research OOD
Smolyan, Bulgaria
DCC Ascendent OOD
Sofia, Bulgaria
SGHAT Dr. Shterev EOOD
Sofia, Bulgaria
Acibadem City Clinic UMHAT Tokuda EAD, Endocrinology
Sofia, Bulgaria
Medical Centre Medical Arts Medico-dental centre
Sofia, Bulgaria
Medical Center Medical Plus EOOD
Varna, Bulgaria
AIPSMC Dr. Evelina Zlatanova EOOD
Varna, Bulgaria
Ocean West Research Clinic
Surrey, British Columbia, Canada
Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
Nova Scotia Hlth Halifax
Halifax, Nova Scotia, Canada
Premier Clinical Trial Research Network (PCTRN)
Hamilton, Ontario, Canada
Wharton Med Clin Trials
Hamilton, Ontario, Canada
Wharton Medical Clinic Clinical Trials (Hamilton)
Hamilton, Ontario, Canada
Hamilton Med Res Group
Hamilton, Ontario, Canada
Milestone Research
London, Ontario, Canada
Ordinace praktického lékaře
Benátky Na Jizerou, Czechia
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.